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By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated
efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on
enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens.
We discuss these innovative strategies and propose how they will impact the future of antibody-
based cancer therapy.Introduction
Specific recognition and elimination of pathological organisms or
malignant cells by antibodies were proposed over a century ago
by Paul Ehrlich, who is credited for conceptualizing the ‘‘magic
bullet’’ theoryof targeted therapy.Over thepast30years, antibody
cancer therapeutics have been developed and used clinically in
an effort to realize the potential of targeted therapy. The diversity
of these targeted approaches reflects the versatility of antibodies
as platforms for therapeutic development (Weiner et al., 2010).
Antibodiesmay target tumor cells by engaging surface antigens
differentially expressed in cancers. For example, rituximab targets
CD20 innon-HodgkinBcell lymphoma, trastuzumab targetsHER2
inbreast cancer, andcetuximab targets EGFR in colorectal cancer
(Table S1 available online). The antibodies can invoke tumor cell
death by blocking ligand-receptor growth and survival pathways.
In addition, innate immune effector mechanisms that engage the
Fc portion of antibodies (Figure S1) via Fc receptors (FcR) are em-
erging as equally important (Jiang et al., 2011). The mechanisms
include antibody-dependent cellular cytotoxicity (ADCC) and
complement-mediated cytotoxicity (CMC); antibody-dependent
cellular phagocytosis (ADCP) is likely relevant as well (Figure 1).
Although unconjugated antibodies have had efficacy,molecular
genetics and chemical modifications to monoclonal antibodies
(mAbs) have advanced their clinical utility. For example, modifica-
tion of immune effector engagement has improved pharmacoki-
netic profiles, and conjugating cytotoxic agents to mAbs has
enhanced targeted therapeutic delivery to tumors. The increasing
facility of antibodymodifications hasmade it possible to construct
diverse and efficacious mAb-based therapeutics (Figure S1).
Structural engineering and alternative targets have also ex-
panded the ability ofmAbs tostimulate adaptive immuneeffectors,
such as T cells, that can induce antitumor activity. Antibodies
directly targeting receptors involved in checkpoint regulation of
immune cells have exhibited preclinical and clinical successes.
Ongoing studies also suggest that antibodies can indirectly elicit
adaptive immunity through antibody-dependent engagement of
immuneeffectormechanisms(Figure1).Overall, thediverseeffects
of antibodies and their putative mechanisms of action suggest
several exciting directions for developing therapeutic strategies.
Some that have achieved recent success are discussed below.Manipulating Antibody Structure
The natural properties of antibodies that enable specific antigen
engagement can be leveraged and improved upon by engi-
neering approaches that increase antitumor activity. One
example is the creation of bispecific antibodies (bsAbs) with
dual affinities for a tumorantigenandeither another tumorantigen
or a target in the tumor microenvironment. As the Fc domain of
mAbs does not directly activate T cells, the activating receptor
for T cells, CD3, is a common target of bsAbs. Catumaxomab is
a bsAb that binds the tumor antigen EpCAM, CD3, and innate
effector cells through an intact Fc portion (Ruf and Lindhofer,
2001). This bsAb, termed a TriomAb, effectively kills tumor cells
in vitro and in vivo and induces protective immunity, most likely
through the induction of memory T cells. Catumaxomab’s suc-
cess inaphase II/III clinical trial led to its approvalby theEuropean
Commission in 2009 for the treatment of malignant ascites. This
success spurred the development of other TriomAbs targeted
against the tumor antigens HER2/neu (ertumaxomab), CD20
(Bi20/FBTA05; NCT01138579 [see Web Resources section
below for information on full urls]), GD2, and GD3 (Ektomun).
A promising approach to directly stimulate T cell immunity with
mAbs is the development of bispecific T cell engager (BiTE)
molecules that target CD3 and either CD19, EpCAM, or EGFR.
Low doses of BiTEs induce antitumor activity, and BiTEs have
the added potential to overcome mutations in signaling path-
ways that classically lead to resistance. In BiTEs, the variable
domains of a CD3-targeted antibody and a tumor antigen-
targeted antibody are genetically linked, rendering it possible
to activate a T cell when it physically engages a tumor cell (Lut-
terbuese et al., 2010). Lysis of bound tumor cells and the accu-
mulation of cytotoxic T cells in the tumor microenvironment
ensues, leading to tumor regression at in vivo doses three orders
of magnitude less than those of the parent antibody (Lutterbuese
et al., 2010). The newly characterized BiTEs directed against
EGFR utilize the parental antibodies cetuximab and panitu-
mumab, with potent antitumor abilities against KRAS- and
BRAF-mutated cells that demonstrate resistance to conven-
tional EGFR antibodies (Lutterbuese et al., 2010). The CD19-
CD3 BiTE demonstrates significant clinical promise in patients
with advanced non-Hodgkin lymphoma (NHL) and is currentlyCell 148, March 16, 2012 ª2012 Elsevier Inc. 1081
Figure 1. Mechanisms of Action of Antibody
Immunotherapy in Cancer
Mechanisms of anticancer antibody therapies are
diverse and represent the versatility of antibody-
based approaches. Here, four different strategies
are depicted. Upper left: direct cytotoxicity, in
whichmAbscan inducedirect cytotoxicity in tumor
cells by perturbing oncogenic signaling pathways
or in which immunoconjugates can carry cytotoxic
agents to targeted cells. Lower left: FcR-mediated
immune effector engagement, in which the Fc
portion of mAbs can engage immune effector
functions, including soluble CMC (through the
membrane attack complex MAC) as well as NK
cells, macrophages, and dendritic cells, through
FcRs, allowing for ADCC, ADCP, and IC uptake.
Upper right: Nonrestricted activation of cytotoxic
T cells, in which tumor-infiltrating CTLs can be
activated against tumor cells—independent of
T cell receptor (TCR) specificity—by engaging
coreceptors on the T cells and tumor antigens.
Lower right: blockade of inhibitory signaling, in
which cytotoxic lymphocytes, including NK cells
and CTLs, express inhibitory receptors for various
ligands that may be expressed by tumor cells.
Antagonistic antibodies that target these inhibitory
receptors can block ligand-receptor interactions
so that targeted cytotoxicity can ensue. These
four strategies enhance tumor cell death, which
can promote phagocytosis of tumor cell antigens,
and induction of adaptive immune responses
(bottom right) in two ways: MHC class I cross-
presentation and priming of cytotoxic T cells and
MHC class II presentation and priming of helper
T cells. These adaptive immune responses can
lead to enhanced—and possibly persistent—
antitumor immunity.being tested in six phase I/II clinical trials. The EpCAM-CD3 BiTE
is in a phase I clinical trial.
An alternative method of creating bsAbs relies on the system-
atic analysis of binding affinities toward a second antigen
after randommutation of the light-chain complementarity-deter-
mining regions (CDRs) of a parent antibody. Using this tech-
nique, bsAbs with two identical Fab regions, targeting VEGFA
and HER2 or HER3 and EGFR, have been developed (Schaefer
et al., 2011). MEHD7945A, an IgG1 antibody that binds to
HER3 and EGFR with high affinity, exhibited equal or better anti-
tumor efficacy than either parent antibody in 12 xenograft
models (Schaefer et al., 2011). Although thismethod has theoret-
ical utility for the development of bsAbs against any combination
of two or more antigens, its potential for systematic applicability
remains to be fully demonstrated.
The CovX-Body method is another recent technique for the
rapid creation of bispecific antibodies (Doppalapudi et al.,
2010). By fusing two peptide pharmacophores together and
linking this complex to a universal scaffold antibody, a bispecific
antibody with known Fc functions can be created. This structure,
classified as a bispecific CovX-Body, is reproducible and spe-
cific and has the potential for widespread adoption. CVX-241,
the first CovX-Body to enter clinical trials (NCT00911898),
targets the angiogenesis ligands VEGFA and Ang2. Preclinically,
CVX-241 exhibited moderate antitumor effects but, when com-
bined with the chemotherapy agent irinotecan, significantly in-
hibited tumor growth (Doppalapudi et al., 2010). Another bsAb,
MM-111, represents an alternative approach to bispecific engi-1082 Cell 148, March 16, 2012 ª2012 Elsevier Inc.neering, based on linking the variable regions from two different
antibodies. MM-111 targets HER2 and HER3 and is in phase I
clinical trials. As the repertoire of cancer targets increases,
dual targeting techniques may enhance clinical efficacy com-
pared to traditional single-antigen targeting approaches.
Stimulating Persistent Immunity
Generation of a persistent antitumor immune response is a pre-
vailing goal of cancer immunotherapy. Antibody therapy can
indirectly stimulate persistent responses against tumor-associ-
ated antigens through induction of adaptive immunity (Figure 1).
Hence, therapeutic antibodies can act to promote vaccine-like
antitumor effects. Tumor cell death can modulate antigen
uptake, maturation, and presentation in antigen-presenting cells
(APCs), which are critical for initiating adaptive immunity (Sauter
et al., 2000). Beyond inducing tumor cell death by blocking
survival pathways, therapeutic antibodies can also coat tumor
cells and mark them for recognition by immune cells. APCs,
such as dendritic cells (DCs) or macrophages, can phago-
cytose antibody-coated tumor cells. Antibodies bound to
soluble antigens in immune complexes (ICs) can also induce
uptake by APCs. Through these various mechanisms of tumor
antigen uptake, tumor contents—not only the antibody-targeted
antigen—can be processed and presented by major histo-
compatibility complexes (MHCs) to activate different adaptive
immune responses. Antigens presented via MHC class II can
prime helper (CD4+) T cell responses important for endogenous
antibody (humoral) immunity. In addition, cross-presentation of
antigen and MHC class I-restricted priming of cytotoxic (CD8+)
T cell, or cytotoxic T lymphocyte (CTL), responses can occur
(Dhodapkar et al., 2002). The induction of these T cell responses
can enable immunological memory to the presented antigens,
which is critical for long-term immunity.
The capacity ofmAbs to induce tumor-directedCTL responses
is intriguing. Intratumoral CTL composition and distribution have
been associated with clinical outcomes (Galon et al., 2006), sug-
gesting the relevance of T cells in antitumor immunity. Moreover,
CTLs can target intracellular antigens that are thought to be inac-
cessible to antibody therapies. Therefore, antibody-initiated
cross-presentation of tumor antigens can be exploited to induce
adaptive immunity that may extend beyond the targeted antigen.
This strategy has been described as the ‘‘vaccinal effect’’ in ritux-
imab therapy of lymphoma (Hilchey et al., 2009) and has been
shown tobe relevant in antibody therapyof solid tumors. Theanti-
body-dependent promotion of adaptive immunity remains an
active and very promising area of research, as the induction of
adaptive immunity can be accompanied by efforts to expand,
shape, and prolong the host immune response. Because tumors
may establish local and systemic immunosuppressive environ-
ments, concomitant efforts to neutralize immunosuppressive
mechanisms may also amplify the vaccinal effect of mAbs.
Modulating the Amplitude of Immune Responses
Following activation, T cells upregulate the expression of inhibi-
tory receptors, which protects against deleterious autoimmunity.
This host-protectivemechanism permits tumors to evade persis-
tent immune control due to localized immune tolerance. This
control is further manipulated by tumors through downregulation
of surface immunogens or through the activation of diverse
immune-suppressive mechanisms. This interplay between the
immune system and tumor cells, termed immunoediting, allows
tumors to escape immune elimination even when tumor-specific
immunity is present (Schreiber et al., 2011).
Ipilimumab, an IgG1 mAb, antagonizes the inhibitory receptor
CTLA-4, which is expressed on activated T cells. Treatment with
this antibody in combination with dacarbazine correlates with
a marked increase in overall survival and progression-free
survival of previously untreated melanoma patients compared
to treatment with dacarbazine alone (Robert et al., 2011). It is
clear from the success of this landmark phase III trial that
harnessing the activity of T cells will have a therapeutic antitumor
benefit, even in the absence of a tumor antigen-targeted
strategy. This clinical efficacy highlights the inherent ability of
the immune system to recognize and eliminate abnormal self
without the aid of tumor-specific therapies.
The PD-1 axis represents another promising immune check-
point pathway to manipulate. PD-1 is expressed on activated T
and B cells and provides a potent inhibitory signal when bound
by ligand. Antibodies inhibiting the PD-1 checkpoint may reacti-
vate T cells by blocking APC inhibition of T cells or by stopping
tumor cells, which often overexpress PD-1 ligands, from inacti-
vating T cells in the tumor microenvironment. In a phase I trial
for refractory solid tumors, Brahmer et al. evaluated an IgG4
mAb, MDX-1106, that recognizes the extracellular domain
of PD-1 with high affinity. The antibody was well tolerated in
38 of the 39 patients treated, resulting in three objectiveresponses (two complete responses) and prompting its further
evaluation in a phase II trial for clear-cell renal cell carcinoma
(NCT01354431) (Brahmer et al., 2010).
Other approaches to enhancing T cell-specific immunity
against tumor cells aim to activate stimulatory receptors,
including 4-1BB, OX40, CD27, CD40, and DR3. Preclinical
models have shown that the stimulation of 4-1BB, OX40, and
CD27 leads to proliferation and cytokine production in T cells
(Croft, 2009). Interestingly, activation of 4-1BB and OX40 can
also inhibit the differentiation and proliferation of regulatory
T cells, which contribute to tumor-derived immunosuppression
(Croft, 2009). Therefore, agonistic antibodies to these TNF
receptors potentially have dual and synergistic immune-
promoting roles. Currently, two 4-1BB agonist antibodies are in
phase I and II clinical trials for NHL and melanoma, respectively
(NCT01307267, NCT00612664), and one agonistic OX40 anti-
body is being studied in a phase I/II and phase II trial for prostate
cancer and melanoma (NCT01303705, NCT01416844).
Although themanipulationof Tcells is currently aprimary focus,
other approaches may leverage the innate immune system. By
blocking the function of inhibitory killer cell immunoglobulin-like
receptors (KIRs), natural killer (NK) cells could elicit a tumor-
specific cytotoxic response without harming normal self cells,
as evidenced by the anti-KIR (KIR2DL1/L2/L3 and KIR2DS1/S2)
antagonist antibody IPH2101, which is currently in numerous
early phase clinical trials (NCT00999830). As a clinical validation
of the immunoediting hypothesis, themanipulation of the immune
system to elicit an antitumor response has the potential to serve
as an efficacious treatment modality across all cancers.
Immunoconjugates: Targeting Cytotoxic Agents
Early efforts to enhance the antitumor effects ofmAbs focused on
boosting their direct cytotoxic effects on targeted cells. Conjuga-
tionof radionuclides (radioimmunotherapies, orRITs), drugs (anti-
body-drug conjugates, or ADCs), toxins (immunotoxins), and
enzymes (antibody-directed enzyme prodrug therapy, or ADEPT)
yielded a multitude of antibodies—or antibody-like molecules—
with varying clinical efficacy. Three conjugated antibodies have
translated into FDA-approved therapies, all for hematological
malignancies. Two are RIT agents targeting CD20 and are indi-
cated for treatment of relapsed and/or rituximab-refractory follic-
ular or low-grade lymphomas: 90Y-ibritumomab tiuxetan and
131I-tositumomab. At least a dozen other RIT agents are in active
development, including ten that target solid tumors (Steiner and
Neri, 2011). The third approved immunoconjugate, brentuximab
vedotin, is an ADC targeting CD30 and carrying the antimitotic
drugmonomethyl auristatin E. Brentuximab vedotin was recently
approved for treatment of anaplastic large cell lymphoma
(NCT00866047) and Hodgkin lymphoma (NCT00848926).
The limited translational success of immunoconjugates
reflects the challenges of developing a highly cytotoxic agent
with acceptable pharmacokinetics and toxicity. RITs can cause
systemic toxicity, and many tumors, particularly solid tumors,
are inaccessible or insensitive to deliverable doses of radiation.
Although a premise of antibody immunotherapy is low toxicity
imparted by specificity, ‘‘tumor-specific’’ antigens are often
more selective than specific. Additionally, generation of neutral-
izing antibodies to recombinant immunoconjugates, such asCell 148, March 16, 2012 ª2012 Elsevier Inc. 1083
immunotoxins, may limit their clinical utility, similar to the limita-
tions associated with murine antibodies (Kreitman et al., 2009).
These challenges have not thwarted attempts to develop
immunoconjugates. Another ADC, trastuzumab-MCC-DM1
(trastuzumab-DM1 or T-DM1), has shown promise in patients
with HER2-positive metastatic breast cancer. A phase III trial
comparing T-DM1 against capecitabine, a prodrug of 5-fluoro-
uracil, plus lapatinib, a tyrosine kinase inhibitor, is underway
(NCT00829166). The most clinically advanced immunotoxin,
BL22, contains an anti-CD22 Fv bound to a modified Pseudo-
monas exotoxin. BL22 has shown significant promise in phase II
trials for the treatment of hairy cell leukemia (Kreitman et al.,
2009). Beyond direct tumor cell cytotoxicity, it is possible that
cytotoxic immunoconjugates could induce antigen-targeted
adaptive immune responses, though this requiresadditional study.
A Longer-Term View
Activating FcRs involved in immune effector activities are impor-
tant for antitumor effects (Clynes et al., 2000). However, two
recent, independent reports have demonstrated that engage-
ment of either activating and inhibitory FcRs (Wilson et al.,
2011) or inhibitory FcR alone (FcgammaRIIB) (Li and Ravetch,
2011) can drive antitumor immune effects of agonistic antibodies
targeting death receptor superfamily members. The compelling
observation that inhibitory FcRs alone drive productive immune
responses is unexpected. Thus, efforts to modify mAb structure
to balance engagement of FcRs will remain a critical component
of antibody development (Jiang et al., 2011). These findings
highlight how antibody therapy can elucidate novel mechanisms
of immune effector activity that may differ from fundamental
understanding in immunology.
An even more basic tenet of antibody therapy is the concept
of targetable antigens. The dogma has been that only soluble
extracellular or cell-surface antigens are accessible targets for
antibodies. Targeting intracellular antigens—particularly onco-
genic or mutated cytosolic proteins specific to tumor cells—
has been left to other membrane-permeable treatment modali-
ties. However, cellular immunotherapy targeting endogenous
intracellular antigens that are processed and presented at the
tumor cell surface, as with the prostate cancer therapy Sipuleu-
cel-T, has already demonstrated its worth.
Remarkably, recent findings suggest that we may have
underestimated the capacity for antibodies to target intracellular
antigens. Guo and colleagues have demonstrated thatmAbs can
effectively target intracellular antigens and inhibit tumor growth in
mouse models (Guo et al., 2011). The capacity for antibodies to
be internalized by tumor cells, thereby allowing for access to
intracellular antigens, may explain this provocative observation.
Targeting intracellular antigens would profoundly broaden anti-
body immunotherapy to include tumor-specificmutated intracel-
lular proteins and other intracellular mediators of cell survival and
proliferation. As this is a nascent area of research, it is only spec-
ulative that intracellular antigen targetingwould provide sufficient
antitumor effect to translate into clinical efficacy. In concert with
targeted strategies that enhance antitumor immunity, even in the
face of immune evasion, tolerance, and suppression, it is
possible to envision a future where combinatorial antibody
approaches transition into cancer immunotherapeutic strategies.1084 Cell 148, March 16, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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